Evidence map›Paper›PMID 30914062›Full record

ArticleBMC pulmonary medicine2019

Reduced transient receptor potential vanilloid 2 expression in alveolar macrophages causes COPD in mice through impaired phagocytic activity.

Hiroaki Masubuchi, Manabu Ueno, Toshitaka Maeno, Koichi Yamaguchi, Kenichiro Hara, Hiroaki Sunaga, Hiroki Matsui, Masahiro Nagasawa, Itaru Kojima, Yuko Iwata and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC pulmonary medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. SCGB1A1 as a Key Regulator of Splenic Immune Dysfunction in COPD: Insights From a Murine Model.International journal of chronic obstructive pulmonary disease · 2025
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Hiroaki MasubuchiDepartment of Allergy and Respiratory Medicine, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan. hmasubuc@gunma-u.ac.jp.ORCID http://orcid.org/0000-0002-8485-4403
Manabu UenoDepartment of Allergy and Respiratory Medicine, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Toshitaka MaenoDepartment of Allergy and Respiratory Medicine, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Koichi YamaguchiDepartment of Allergy and Respiratory Medicine, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Kenichiro HaraDepartment of Allergy and Respiratory Medicine, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Hiroaki SunagaDepartment of Cardiovascular Medicine, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Hiroki MatsuiDepartment of Laboratory Sciences, Gunma University Graduate School of Health Sciences, 3-39-22 Showa-machi, Maebashi, 371-8511, Gunma, Japan.
Masahiro NagasawaInstitute for Molecular and Cellular Regulation, Gunma University, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8512, Japan.
Itaru KojimaInstitute for Molecular and Cellular Regulation, Gunma University, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8512, Japan.
Yuko IwataDepartment of Molecular Physiology, National Cerebral and Cardiovascular Center Research Institute, 5-7-1 Fujisirodai, Suita, Osaka, 565-8565, Japan.
Shigeo WakabayashiDepartment of Pharmacology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-city, 569-8686, Osaka, Japan.
Masahiko KurabayashiDepartment of Allergy and Respiratory Medicine, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Gunma University · JPNational Cerebral and Cardiovascular Center · JPOsaka Medical and Pharmaceutical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDefective phagocytosis in alveolar macrophages is associated with chronic obstructive pulmonary disease (COPD). Transient receptor potential cation channel subfamily V member 2 (TRPV2), a type of nonselective cation channel pertinent to diverse physiological functions, regulates macrophage phagocytosis. However, the role of TRPV2 in COPD remains poorly understood. Here, we explored the role of TRPV2 in the development of COPD.

methodsMacrophage TRPV2 expression and phagocytosis function were measured in MH-S cells (a murine alveolar macrophage cell line) and a cigarette smoke exposure mouse model.

resultsTRPV2 expression and phagocytosis function were reduced when MH-S cells were exposed to cigarette smoke extract (CSE). TRPV2 knockdown by siRNA decreased phagocytosis in MH-S cells. Consistently, TRPV2 expression was reduced in alveolar macrophages prepared from bronchoalveolar lavage samples of mice which were exposed to cigarette smoke for 2 months. In addition, the alveolar space was progressively enlarged during development in TRPV2 knockout (TRPV2KO) mice. Moreover, exposure to cigarette smoke for 2 months significantly induced alveolar space enlargement in TRPV2KO mice, but not in wild-type (WT) mice. The phagocytic function of alveolar macrophages from TRPV2KO mice was reduced, compared with macrophages from WT mice.

conclusionsTRPV2 expression is profoundly downregulated in alveolar macrophages at early time points of cigarette smoke exposure. Reduced TRPV2-mediated phagocytic function renders the lung susceptible to cigarette smoke-induced alveolar space enlargement. TRPV2 may provide a therapeutic target for COPD induced by cigarette smoke.

Indexed as

AnimalsCalcium ChannelsCell LineCells, CulturedCigarette SmokingDisease Models, AnimalFemaleLungMacrophages, AlveolarMiceMice, Inbred C57BLMice, KnockoutPhagocytosisPulmonary Disease, Chronic ObstructiveTRPV Cation ChannelsCalcium ChannelsTrpv2 protein, mouseTRPV Cation ChannelsAlveolar macrophageChronic obstructive pulmonary disease (COPD)Cigarette smokePhagocytosisTransient receptor potential V2 (TRPV2)

Identifiers

PMID30914062
PMCPMC6434859
OpenAlexW2901715783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.